Zydus Lifesciences in-licenses critical drug MonoFerric for CKD patients from Pharmacosmos A/S of Denmark
MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.
New Delhi: Zydus Lifesciences Ltd. has announced that the company has acquired rights to market MonoFerric (iron isomaltoside) injections in India and Nepal from Denmark based Pharmacosmos A/S.
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile. MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.
MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch.
Speaking on the development Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "Iron Deficiency is a severe healthcare challenge and also impacts the quality of life more so in CKD patients. With this introduction, we bring a novel solution to these patients and with our strong lastmile delivery, we will enable access to this critical therapy."
Zydus group is headquartered in Ahmedabad, India. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
Zydus is amongst the top players in the Nephrology segment with a super-specialty portfolio with brands like Oxemia, Zyrop, Renocrit, Kbind, Grafalon, Tacromus and Mycomune.
Read also: Zydus Lifecsciences begins Desidustat Phase IV trial in patients with CKD induced anemia
Pharmacosmos A/S is a specialist in iron therapy developing, manufacturing and marketing medicines for the treatment of iron deficiency anemia in humans and animals. Furthermore, the company specialises in developing and producing advanced carbohydrates for pharmaceutical and technical uses.
